Literature DB >> 17706971

The therapeutic plasticity of neural stem/precursor cells in multiple sclerosis.

Stefano Pluchino1, Gianvito Martino.   

Abstract

Adult multipotent neural stem/precursor cells (NPCs) have the capacity to self-renew and generate functional differentiated cells (e.g. neurons, astrocytes or oligodendrocytes) within discrete tissue-specific germinal niches, such as the subventricular zone of the lateral ventricles and the subgranular zone of the dentate gyrus of the hippocampus. Due to their intrinsic plasticity NPCs can be considered an essential part of the cellular mechanism(s) by which the central nervous system (CNS) tries to repair itself after an injury and, as a consequence, they also represents an attractive therapeutic tool for the treatment of neurological disorders. Here we will discuss not only the role of NPC-based transplantation therapies in multiple sclerosis (MS) but also recent data suggesting that endogenous NPCs, while contributing to CNS repair in MS, may also become the target of the disease itself.

Entities:  

Mesh:

Year:  2007        PMID: 17706971     DOI: 10.1016/j.jns.2007.07.020

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  26 in total

Review 1.  Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations.

Authors:  Eilhard Mix; Hans Meyer-Rienecker; Uwe K Zettl
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

2.  Effect of Fingolimod on Neural Stem Cells: A Novel Mechanism and Broadened Application for Neural Repair.

Authors:  Yuan Zhang; Xing Li; Bogoljub Ciric; Cun-Gen Ma; Bruno Gran; Abdolmohamad Rostami; Guang-Xian Zhang
Journal:  Mol Ther       Date:  2016-12-28       Impact factor: 11.454

3.  Modified thalamocortical model: a step towards more understanding of the functional contribution of astrocytes to epilepsy.

Authors:  Mahmood Amiri; Fariba Bahrami; Mahyar Janahmadi
Journal:  J Comput Neurosci       Date:  2012-03-01       Impact factor: 1.621

4.  Transplantation of Fas-deficient or wild-type neural stem/progenitor cells (NPCs) is equally efficient in treating experimental autoimmune encephalomyelitis (EAE).

Authors:  Charles Hackett; Julia Knight; Yang Mao-Draayer
Journal:  Am J Transl Res       Date:  2014-01-15       Impact factor: 4.060

Review 5.  Inflammation induced neurological handicap processes in multiple sclerosis: new insights from preclinical studies.

Authors:  Klaus G Petry; Bruno Brochet; Vincent Dousset; Jean Rodolphe Vignes; Claudine Boiziau
Journal:  J Neural Transm (Vienna)       Date:  2010-06-23       Impact factor: 3.575

6.  1,25-Dihydroxyvitamin D3 enhances neural stem cell proliferation and oligodendrocyte differentiation.

Authors:  Hasti Atashi Shirazi; Javad Rasouli; Bogoljub Ciric; Abdolmohamad Rostami; Guang-Xian Zhang
Journal:  Exp Mol Pathol       Date:  2015-02-11       Impact factor: 3.362

7.  LINGO-1-Fc-Transduced Neural Stem Cells Are Effective Therapy for Chronic Stage Experimental Autoimmune Encephalomyelitis.

Authors:  Xing Li; Yuan Zhang; Yaping Yan; Bogoljub Ciric; Cun-Gen Ma; Jeannie Chin; Mark Curtis; Abdolmohamad Rostami; Guang-Xian Zhang
Journal:  Mol Neurobiol       Date:  2016-06-25       Impact factor: 5.590

8.  The effect of interferon-beta on mouse neural progenitor cell survival and differentiation.

Authors:  Marek Hirsch; Julia Knight; Mari Tobita; John Soltys; Hillel Panitch; Yang Mao-Draayer
Journal:  Biochem Biophys Res Commun       Date:  2009-07-18       Impact factor: 3.575

Review 9.  Strategies for protecting oligodendrocytes and enhancing remyelination in multiple sclerosis.

Authors:  Jane M Rodgers; Andrew P Robinson; Stephen D Miller
Journal:  Discov Med       Date:  2013-08       Impact factor: 2.970

Review 10.  Paving the axonal highway: from stem cells to myelin repair.

Authors:  Raniero L Peru; Nicole Mandrycky; Brahim Nait-Oumesmar; Q Richard Lu
Journal:  Stem Cell Rev       Date:  2008-12       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.